click on circles to display study description...
cediranib plus fulvestrant (n=-9) vs. fulvestrant (n=-9)
randomized controlled trial
cediranib plus fulvestrant
cediranib: PO 45mg/day / fulvestrant: IM 500mg day 1 and 250mg days 15, 29 and every 28 days thereafter
fulvestrant
fulvestrant: IM 500mg day 1 and 250mg days 15, 29 and every 28 days thereafter
la/mBC - HR-positive - 1st line (L1)
exclusion criteria: prior biological therapy (except trastuzumab),fulvestrant treatment, >1 course of prior systemic cytotoxicchemotherapy for MBC
double blind
from 19 centers in Australia, Brazil and the USA
P2 / PFS at 1-sided at 10% significance level
powered by vis.js Network